SCHEMBL634528

SCHEMBL634528

C1CNC2=C(C1)NCNC2

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
OR51E2 Q9H255 1/20 0.33
LMNA P02545 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22908210 0.79
SCHEMBL8866832 0.79 OR51E2 (0.47) OR51E2LMNAHSD17B10
SCHEMBL28069093 0.79
SCHEMBL11720970 0.70 CRBN (0.50) OR51E2LMNAHSD17B10
SCHEMBL29056281 0.68
SCHEMBL2228088 0.65
SCHEMBL5056719 0.64 OR51E2 (0.39) OR51E2LMNAHSD17B10
SCHEMBL19689034 0.64 OR51E2 (0.39) OR51E2LMNAHSD17B10
SCHEMBL6824902 0.63 PNMT (0.37)
SCHEMBL20100276 0.62 OR51E2 (0.33) OR51E2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2302000-B1 CURABLE COMPOSITION AND CATALYST COMPOSITION KANEKA CORP (JP) 2016-11-16 EP disclosed
US-9051501-B2 Curable composition and catalyst composition KANEKA CORPORATION (JP) 2015-06-09 US disclosed
EP-2088173-B1 CURABLE COMPOSITION AND CATALYST COMPOSITION KANEKA CORP (JP) 2012-02-22 EP disclosed
EP-2302000-A1 Curable composition and catalyst composition KANEKA CORPORATION (JP) 2011-03-30 EP disclosed
US-20100041810-A1 CURABLE COMPOSITION AND CATALYST COMPOSITION KANEKA CORPORATION (JP) 2010-02-18 US disclosed
EP-2088173-A1 CURABLE COMPOSITION AND CATALYST COMPOSITION Kaneka Corporation (JP) 2009-08-12 EP disclosed